Neuroimaging and therapeutics in movement disorders

被引：33

作者：

Eckert T. ^{[1
,2
]}

Eidelberg D. ^{[2
,3
,4
]}

机构：

[1] Dept. of Neurology II and Psychiatry, University of Magdeburg

[2] Center for Neurosciences, Institute for Medical Research, N. Shore-Long Isl. Jewish Hlth. S., Manhasset

[3] Department of Neurology, New York Univ. School of Medicine, New York

[4] Center for Neurosciences, Institute for Medical Research, N. Shore-Long Isl. Jewish Hlth. S., Manhasset, NY 11030

来源：

NeuroRX | 2005年 / 2卷 / 2期

关键词：

Dystonia; Huntington's disease; Magnetic resonance imaging (MRI); Movement disorders; Parkinson's disease; Positron emission tomography (PET); Tourette's syndrome;

D O I：

10.1602/neurorx.2.2.361

中图分类号：

学科分类号：

摘要：

In this review, we discuss the role of neuroimaging in assessing treatment options for movement disorders, particularly Parkinson's disease (PD). Imaging methods to assess dopaminergic function have recently been applied in trials of potential neuroprotective agents. Other imaging methods using regional metabolism and/or cerebral perfusion have been recently introduced to quantify the modulation of network activity as an objective marker of the treatment response. Both imaging strategies have provided novel insights into the mechanisms underlying a variety of pharmacological and stereotaxic surgical treatment strategies for PD and other movement disorders.

引用

页码：361 / 371

页数：10

共 124 条

[41]

Eidelberg D., Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., Et al., Assessment of disease severity in parkinsonism with fluorine-18- fluorodeoxyglucose and PET, J Nucl Med, 36, pp. 378-383, (1995)

[42]

Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Mandel F., Alexander G.E., Et al., The metabolic topography of normal aging, J Cereb Blood Flow Metab, 16, pp. 385-398, (1996)

[43]

Lozza C., Baron J.C., Eidelberg D., Mentis M.J., Carbon M., Marie R.M., Executive processes in Parkinson's disease: FDG-PET and network analysis, Hum Brain Mapp, 22, pp. 236-245, (2004)

[44]

Moeller J.R., Eidelberg D., Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing, Brain, 120, pp. 2197-2206, (1997)

[45]

Eidelberg D., Moeller J.R., Dhawan V., Sidtis J.J., Ginos J.Z., Strother S.C., Et al., The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies, Mov Disord, 5, pp. 203-213, (1990)

[46]

Eidelberg D., Moeller J.R., Kazumata K., Antonini A., Sterio D., Dhawan V., Et al., Metabolic correlates of pallidal neuronal activity in Parkinson's disease, Brain, 120, pp. 1315-1324, (1997)

[47]

Alsop D.C., Casement M., Press D., Increased hippocampal perfusion in early Alzheimer's disease, Proc Intl Soc Mag Reson Med, 11, (2003)

[48]

Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Et al., Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease, Am J Psychiatry, 159, pp. 746-754, (2002)

[49]

Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., Lozano A.M., The subthalamic nucleus in the context of movement disorders, Brain, 127, pp. 4-20, (2004)

[50]

Volkmann J., Deep brain stimulation for the treatment of Parkinson's disease, J Clin Neurophysiol, 21, pp. 6-17, (2004)

← 1 2 3 4 5 6 7 8 9 10 →